Cardurion Pharmaceuticals
MA - Burlington
PharmaceuticalFocus: Cardiovascular treatments
Cardurion Pharmaceuticals is a life sciences company focused on Cardiovascular treatments.
CardiovascularNeurologyMetabolic Diseases
Open Jobs
0
Pipeline & Clinical Trials
CRD-740
Clinical PharmacologyClinical Trials (1)
NCT05437094Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
Phase 1IMR-687
Sickle Cell DiseaseClinical Trials (1)
NCT02998450A Study of IMR-687 in Healthy Adult Volunteers
Phase 1CRD-740
Heart FailureClinical Trials (1)
NCT05409183Effectiveness of CRD-740 in Heart Failure
Phase 2Phase 2
Clinical Trials (1)
NCT05312021Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
Phase 2IMR-687
Sickle Cell DiseaseClinical Trials (1)
NCT03401112A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Phase 2IMR-687
Sickle Cell DiseaseClinical Trials (1)
NCT04474314A Study of IMR-687 in Subjects With Sickle Cell Disease
Phase 2CRD-4730
CPVT1Clinical Trials (1)
NCT06005428Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Phase 2IMR-687
β ThalassemiaClinical Trials (1)
NCT04411082A Study of IMR-687 in Subjects With Beta Thalassemia
Phase 2Phase 2
Clinical Trials (1)
NCT06658899A Phase 2 Study of CRD-4730 in CPVT
Phase 2Tovinontrine
Heart FailureClinical Trials (1)
NCT06215911A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
Phase 2Tovinontrine
Heart FailureClinical Trials (1)
NCT06215586Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 11 clinical trials